Sign up Australia
Proactive Investors - Run By Investors For Investors

AusCann Group signs a medical cannabis deal with Columbia based Khiron Life Sciences

The companies will collaborate on activities to develop cannabinoid medicines as a medical option in Chile.
medical cannabis
Khiron is listed on the TSX Venture Exchange in Canada

AusCann Group Holdings Ltd’s (ASX:AC8) Chilean joint venture DayaCann has signed a memorandum of understanding (MoU) with Columbian medical cannabis company Khiron Life Sciences Corp (CVE:KHRN).

Khiron has its core operations in Colombia and aims to address the unmet medical needs in a market of over 620 million people in Latin America.

The MoU contemplates a method of collaboration through which new alternatives of medical cannabis are offered to patients in Chile.

To achieve this, the parties will engage in cultivation, manufacturing, pedagogical, scientific and other activities that present cannabinoid medicines as a viable medical option.

READ: AusCann Group commences trading in the US increasing global exposure

As part of the agreement, Khiron will provide funds to support the development of these activities.

Under the MoU, DayaCann will provide cultivation and manufacturing services to Khiron.

AusCann and Fundación Daya formed DayaCann in 2016 with the aim of becoming Latin America’s leading medicinal cannabis group.

It is worth noting that DayaCann is the only company in Chile to hold a medical cannabis production licence.

 

DayaCann has already completed two harvests at its 30-hectare facility yielding a total of over 1000 kilograms of dried cannabis flower.

A portion of this cannabis is being used by Chilean pharmaceutical manufacturing group, Knop Laboratories, to create medical cannabis products available to Chilean patients via a special access scheme.

READ: Auscann Group makes steady progress towards production of cannabinoid medicines

AusCann managing director Elaine Darby said: “We look forward to working with Khiron through our joint venture DayaCann.

“To be supplying them high quality cannabinoid medicines and working together on addressing the needs of the Latin American market.

“The MoU will not only expand DayaCann’s presence in Chile, but also give DayaCann wider access to the Latin American market.”

View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds
Oncoprex
Thu
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use